You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -7,850.0% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -2.3 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 287.4 | 0.0 |
| Price / Book value | 4.4 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 0.0% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 0.16 | -6.31 | -4.54p | -11.5 | 0.0 | n/a | n/a | 0.0% |
| 2017-12-31 | 0.15 | -7.00 | -4.75p | -35.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | 0.08 | -7.96 | -5.19p | -2.3 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 0.08 | -6.74 | -3.99p | -4.0 | 0.0 | n/a | n/a | 0.0% |
| ImmuPharma clarifies next steps for phase 3 Lupuzor trial Sharecast News | 09 Feb |
|---|---|
| ImmuPharma gets December date for FDA meeting Sharecast News | 20 Nov |
| ImmuPharma confirms continued FDA delays for Lupuzor Sharecast News | 11 Sep |
| Second Price Monitoring Extn | 25-Feb-21 16:41 |
|---|---|
| Price Monitoring Extension | 25-Feb-21 16:35 |
| Update- scheduled Phase 3 trials in lupus patients | 09-Feb-21 07:00 |
| Appointment of Company Secretary | 18-Jan-21 09:01 |
| Holding(s) in Company | 04-Jan-21 07:10 |